NHS National Framework for Tafamidis
The value below is a framework or dynamic market ceiling: the maximum
that could be spent across all call-offs, not the value of a single contract.
Aggregate figures on this site exclude these to avoid double counting.
key details
| Value | £12,000,000 (£14,400,000 inc. VAT) |
|---|---|
| Status | planned |
| Category (CPV) | 33600000 |
| Region | North East, North West, East Midlands, West Midlands, East of England, South East, South West |
| Procedure | open |
| SME suitable | Yes |
| OCID | ocds-h6vhtk-068921 |
description
Project title: NHS National Framework for Tafamidis
Offer reference number: CM/TNS/26/5750
Suppliers who are planning to introduce the molecule(s) detailed in the framework title, or who have any questions regarding a potential upcoming procurement exercise, are invited to contact the MPSC New Market Developments Team.
Please email barbara.sly@nhs.net, marie.graney1@nhs.net, and katie.noonan@nhs.net
notice history
3 notices published against this procurement.
| Published | Type | Regime | Notice |
|---|---|---|---|
| 23 Apr 2026 | Pipeline notice (UK1) | Procurement Act 2023 | 036871-2026 |
| 8 May 2026 | Preliminary market engagement (UK2) | Procurement Act 2023 | 042203-2026 |
| 14 Jul 2026 | Pipeline notice (UK1) | Procurement Act 2023 | 066484-2026 |
more from NHS England
- Exam Support Packages for EoE GP Registrars · 24 Jul 2026
- Refer a Patient - Adult ECMO 2026/27 · 23 Jul 2026
- Higher Specialist Scientist Training Programme (HSST) · £42,186,231 · 23 Jul 2026
- Imaging National Lecture Series · 22 Jul 2026
- NHS National Framework for Lenvatinib · £35,833,000 · 22 Jul 2026
- The Practice Education Facilitator role in Return to Practice · £20,000 · 22 Jul 2026
- Pharmacy Technician Clinical Skills Development · £300,000 · 22 Jul 2026
- NHS National Framework for Ferric Carboxymaltose injection · £62,633,000 · 21 Jul 2026
all contracts from this buyer →
similar contracts awarded
Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.
- NHS Branded Medicines - Tranche B - London & South of England - 1 September 2026 · NHS England · £592,363,416
- NHS National Generics Pharmaceuticals - Supply Chain Resilience · NHS England · £52,447,296
- Generic, Branded Generic & Proprietary Medicinal Products - Group 18 · Regional Business Services Organisation, Procurement and Logistics Service · £1,800,000,000
- Generic Drugs – Injections/Infusions 2 · NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · £6,535,850
- NP90726m Vedolizumab (Entyvio®) · The Common Services Agency (more commonly known as Public Services Delivery Scotland) (PSD Scotland)
- Transitional Drugs 7 · NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · £53,566,932
- Combined Needles and Syringes Lot 1 · Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency · £15,264,000
- LW158 IMP Support (FAME) · Liverpool School of Tropical Medicine · £0
source
Published on Find a Tender. Contact details for named individuals are not reproduced on this site.